Jorge Nieva, MD, Discusses the Impact of IMpower010 and New Trials in Progress for Early-Stage NSCLC

Video

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Jorge Nieva, MD, from Keck School of Medicine of University of Southern California, about how IMpower010 (NCT02486718) made a big impact at this year’s meeting. The trial examined atezolizumab (Tecentriq) and compared it with best supportive care therapy after adjuvant chemotherapy in patients with resected early-stage non–small cell lung cancer. Results from this study indicated that the trial met its primary end point of disease-free survival superiority with atezolizumab (HR, 0.79; 95% CI, 0.64-0.96; 2-sided P = .0205), with overall survival data still immature.

Transcript:

I’m a lung cancer doctor, [and I’m most excited about IMpower010]. I think this will be the biggest splash that comes out [ASCO]. There’s going to be 6 trials in the works asking the same question [of how will adjuvant therapy affect early stage NSCLC]. They’re all going to come out sometime later. I don’t think any of those 6 trials are reporting out at ASCO.

Reference

Wakelee H, Altorki N, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2021;39(suppl 15):8500. doi: 10.1200/JCO.2021.39.15_suppl.8500

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
A panel of 3 experts on lung cancer
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Related Content